Market closed
QIAGEN/QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Ticker
QGEN
Sector
Trading on
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,900
Website
QIAGEN Metrics
BasicAdvanced
$9.4B
Market cap
129.26
P/E ratio
$0.33
EPS
0.40
Beta
-
Dividend rate
Price and volume
Market cap
$9.4B
Beta
0.4
52-week high
$47.44
52-week low
$35.81
Average daily volume
1.2M
Financial strength
Current ratio
1.768
Quick ratio
1.225
Long term debt to equity
26.692
Total debt to equity
41.16
Interest coverage (TTM)
3.57%
Management effectiveness
Return on assets (TTM)
1.75%
Return on equity (TTM)
2.07%
Valuation
Price to earnings (TTM)
129.265
Price to revenue (TTM)
4.823
Price to book
2.75
Price to tangible book (TTM)
15.34
Price to free cash flow (TTM)
23.093
Growth
Revenue change (TTM)
-1.90%
Earnings per share change (TTM)
-78.50%
3-year revenue growth (CAGR)
-3.95%
3-year earnings per share growth (CAGR)
-46.35%
What the Analysts think about QIAGEN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for QIAGEN stock.
QIAGEN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
QIAGEN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
QIAGEN News
AllArticlesVideos
QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications
GlobeNewsWire·2 weeks ago
QIAGEN N.V. to release results for Q3 2024 and hold webcast
GlobeNewsWire·2 weeks ago
Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $9.4B as of October 24, 2024.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 129.26 as of October 24, 2024.
Does QIAGEN stock pay dividends?
No, QIAGEN (QGEN) stock does not pay dividends to its shareholders as of October 24, 2024.
When is the next QIAGEN dividend payment date?
QIAGEN (QGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.